Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RMD Stock Forecast 2026-2027
$232.41
Current Price
$33.92B
Market Cap
Buy 11
Hold 7
Sell 1
Wall St Analyst Ratings
Distance to RMD Price Targets
+48.4%
To High Target of $345.00
+29.1%
To Median Target of $300.00
-1.0%
To Low Target of $230.00
RMD Price Momentum
-8.1%
1 Week Change
-8.0%
1 Month Change
+5.8%
1 Year Change
-3.5%
Year-to-Date Change
-20.9%
From 52W High of $293.81
+16.3%
From 52W Low of $199.92
📊 TOP ANALYST CALLS
Did RMD Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if ResMed is one of their latest high-conviction picks.
Latest RMD Stock Price Targets & Analyst Predictions
Based on our analysis of 22 Wall Street analysts, RMD has a bullish consensus with a median price target of $300.00 (ranging from $230.00 to $345.00). The overall analyst rating is Buy (7.8/10). Currently trading at $232.41, the median forecast implies a 29.1% upside. This outlook is supported by 11 Buy, 7 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Laura Sutcliffe at Citigroup, projecting a 48.4% upside. Conversely, the most conservative target is provided by Lyanne Harrison at B of A Securities, suggesting a 1.0% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RMD Analyst Ratings
11
Buy
7
Hold
1
Sell
RMD Price Target Range
Low
$230.00
Average
$300.00
High
$345.00
Current: $232.41
Latest RMD Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RMD.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 2, 2026 | Citigroup | Laura Sutcliffe | Buy | Maintains | $345.00 |
| Jan 30, 2026 | RBC Capital | Craig Wong-Pan | Outperform | Maintains | $314.00 |
| Jan 30, 2026 | Piper Sandler | Adam Maeder | Neutral | Maintains | $275.00 |
| Jan 30, 2026 | Stifel | Jonathan Block | Hold | Maintains | $265.00 |
| Jan 30, 2026 | Wells Fargo | Nathan Treybeck | Equal-Weight | Maintains | $270.00 |
| Dec 18, 2025 | Stifel | Jonathan Block | Hold | Maintains | $260.00 |
| Dec 16, 2025 | Baird | Joe Vruwink | Neutral | Downgrade | $275.00 |
| Nov 3, 2025 | Baird | Joe Vruwink | Outperform | Maintains | $300.00 |
| Oct 31, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $299.00 |
| Oct 31, 2025 | RBC Capital | Craig Wong-Pan | Outperform | Maintains | $303.00 |
| Oct 31, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $300.00 |
| Oct 21, 2025 | Morgan Stanley | Sean Laaman | Overweight | Maintains | $304.00 |
| Oct 13, 2025 | Wells Fargo | Nathan Treybeck | Equal-Weight | Initiates | $280.00 |
| Sep 18, 2025 | Citigroup | Laura Sutcliffe | Buy | Initiates | $330.00 |
| Aug 1, 2025 | Keybanc | Brett Fishbin | Overweight | Maintains | $298.00 |
| Aug 1, 2025 | Piper Sandler | Adam Maeder | Neutral | Maintains | $270.00 |
| Aug 1, 2025 | Stifel | Jonathan Block | Hold | Maintains | $270.00 |
| Aug 1, 2025 | RBC Capital | Craig Wong-Pan | Outperform | Maintains | $300.00 |
| Aug 1, 2025 | UBS | Laura Sutcliffe | Buy | Maintains | $325.00 |
| Aug 1, 2025 | Mizuho | Anthony Petrone | Outperform | Maintains | $290.00 |
ResMed Inc. (RMD) Competitors
The following stocks are similar to ResMed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ResMed Inc. (RMD) Financial Data
ResMed Inc. has a market capitalization of $33.92B with a P/E ratio of 23.0x. The company generates $5.40B in trailing twelve-month revenue with a 27.5% profit margin.
Revenue growth is +11.0% quarter-over-quarter, while maintaining an operating margin of +35.2% and return on equity of +25.7%.
Valuation Metrics
Market Cap
$33.92B
Enterprise Value
$33.29B
P/E Ratio
23.0x
PEG Ratio
1.6x
Price/Sales
6.3x
Growth & Margins
Revenue Growth (YoY)
+11.0%
Gross Margin
+61.8%
Operating Margin
+35.2%
Net Margin
+27.5%
EPS Growth
+13.9%
Financial Health
Cash/Price Ratio
+4.2%
Current Ratio
3.1x
Debt/Equity
13.4x
ROE
+25.7%
ROA
+14.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
ResMed Inc. (RMD) Business Model
About ResMed Inc.
What They Do
Develops medical devices for respiratory disorders.
Business Model
The company generates revenue through the sale of advanced medical devices, such as CPAP machines and diagnostic tools, as well as cloud-based software solutions for remote patient monitoring. Its business model is supported by two segments: Sleep and Breathing Health, which focuses on devices for treating sleep apnea, and Residential Care Software, which provides management solutions for long-term care facilities.
Additional Information
ResMed has a strong global presence and is well-positioned to meet the increasing demand for effective treatments for respiratory and sleep disorders. The integration of digital health solutions enhances patient care and provides recurring revenue streams, showcasing the company's commitment to innovation and improving healthcare outcomes.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
10,600
CEO
Mr. Michael J. Farrell BE, MBA, SM
Country
United States
IPO Year
1995
Website
www.resmed.comResMed Inc. (RMD) Latest News & Analysis
Latest News
3 Reasons Not to Sleep on ResMed Stock
3 days ago
Quick Summary
ResMed is experiencing growth and investing in digital technologies. The company's stock is currently considered attractively priced.
Why It Matters
ResMed's growth and investment in digital technologies signal potential for future earnings increases, while its attractive stock price presents a buying opportunity for investors.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
A global survey reveals 53% of respondents prioritize sleep for health, but over half achieve quality sleep only four nights a week or less, indicating a growing awareness yet an action gap.
Why It Matters
Growing awareness of sleep health may drive demand for sleep-related products and services, influencing market trends and investment opportunities in health and wellness sectors.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
ResMed (RMD) stock is trading at a low price. The company shows reasonable growth, solid cash flow, low debt, and is considered fairly valued for potential investors.
Why It Matters
ResMed's low stock price combined with its growth potential, strong cash flow, low debt, and fair valuation may present an attractive buying opportunity for discerning investors.
Source: Forbes
Market Sentiment:
Positive
Quick Summary
Resmed is opening a new distribution center in Greenwood, Indiana, set to begin operations in 2027, enhancing its U.S. presence and distribution capacity in North America.
Why It Matters
Resmed's new distribution center enhances its U.S. operations, potentially increasing efficiency and sales, which may positively impact revenue growth and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The GARP strategy may be effective for creating a profitable stock portfolio. Recommended stocks include RL, EAT, FTI, and RMD for value and growth potential.
Why It Matters
The GARP strategy highlights stocks like RL, EAT, FTI, and RMD, suggesting potential value and growth opportunities, which could enhance portfolio performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Invesco International Growth Fund underperformed in industrials, consumer discretionary, and communication services but outperformed in financials, health care, and energy due to stock selection.
Why It Matters
The Invesco International Growth Fund's stock selection strategy led to mixed performance across sectors, indicating potential volatility and risk for investors focused on specific industries.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About RMD Stock
What is ResMed Inc.'s (RMD) stock forecast for 2026?
Based on our analysis of 22 Wall Street analysts, ResMed Inc. (RMD) has a median price target of $300.00. The highest price target is $345.00 and the lowest is $230.00.
Is RMD stock a good investment in 2026?
According to current analyst ratings, RMD has 11 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $232.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RMD stock?
Wall Street analysts predict RMD stock could reach $300.00 in the next 12 months. This represents a 29.1% increase from the current price of $232.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is ResMed Inc.'s business model?
The company generates revenue through the sale of advanced medical devices, such as CPAP machines and diagnostic tools, as well as cloud-based software solutions for remote patient monitoring. Its business model is supported by two segments: Sleep and Breathing Health, which focuses on devices for treating sleep apnea, and Residential Care Software, which provides management solutions for long-term care facilities.
What is the highest forecasted price for RMD ResMed Inc.?
The highest price target for RMD is $345.00 from Laura Sutcliffe at Citigroup, which represents a 48.4% increase from the current price of $232.41.
What is the lowest forecasted price for RMD ResMed Inc.?
The lowest price target for RMD is $230.00 from Lyanne Harrison at B of A Securities, which represents a -1.0% decrease from the current price of $232.41.
What is the overall RMD consensus from analysts for ResMed Inc.?
The overall analyst consensus for RMD is bullish. Out of 22 Wall Street analysts, 11 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $300.00.
How accurate are RMD stock price projections?
Stock price projections, including those for ResMed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 4:26 PM UTC